To eliminate the threat of type 1 diabetes (T1D) for future generations, the JDRF Prevention Program teams up with allies in academia, industry and government to fund groundbreaking research, and then translates this knowledge into therapies that can stop T1D from developing.
People are being diagnosed with T1D at a growing rate. T1D is not preventable, and there is no cure—yet. At JDRF, we have developed significant knowledge about the causes of T1D. As we increase our understanding of these causes, we will also uncover ways to prevent them from occurring. Until we have found ways to prevent T1D, we must stop or slow its progression during its earliest stages.
so people will know their risk before they develop symptoms
so people are insulin-free for longer
so no one needs to worry about T1D again
“I’ve had type 1 diabetes since I was a kid. Now I’m married, and I worry about my children. For me to know if they are likely to develop type 1 diabetes, and be able to take steps to protect them, would be tremendously powerful.” John H.32 years old, diagnosed at age 4
“I’ve had type 1 diabetes since I was a kid. Now I’m married, and I worry about my children. For me to know if they are likely to develop type 1 diabetes, and be able to take steps to protect them, would be tremendously powerful.”
John H.32 years old, diagnosed at age 4
Our research into prevention technologies is just one potential pathway to finding a cure.Explore JDRF’s ambitious research portfolio. JDRF is working relentlessly to prevent, treat and cure T1D and its complications.
JDRF-supported study findings suggest researchers are narrowing in on factors that may cause T1D. The findings could be an important step toward a key JDRF goal: preventing development of T1D in at-risk individuals.
Armed with the knowledge that T1D begins well before symptoms appear, researchers test different ways to interrupt disease progression and prevent the onset of symptoms in T1D.
JDRF T1D Fund invests in Provention Inc.’s lead program, which aims to potentially reduce new T1D cases by 50 percent.
IBM and JDRF are developing machine learning methods to analyze years of global T1D research data and identify factors leading to the onset of T1D in children--the first precision medicine effort in T1D.
To date, more than $115 million has been invested by JDRF in prevention research. One day, T1D will be like polio or measles, and we will only read about it in our vaccination records.
Press Release
Community Story
